News & Events
-
The Importance of Follow-up Screening
Terri Ann DiJulio, a long-time lung cancer survivor who has overcome three lung cancer diagnoses, talks about the importance of follow-up screenings for lung cancer, family history considerations, and...
-
HOPE Summit
Make friends and get savvy about life with lung cancer! Each year, LUNGevity Foundation brings together patients and caregivers to build friendships and learn from reliable experts... -
Finding Clinical Trials for Lung Cancer: Tools and Resources
Clinical trials are an important option for patients because the newest treatment approaches, not available otherwise, are being tested in them. Clinical trial research leads to... -
Fuel for the Future: Good Nutrition for the Lung Cancer Community
Learn valuable information about good nutrition that can help you live well through lung cancer treatment and beyond. Gain insight and tips from Oncology Dietitian Lori Bumbaco, MS... -
Emotional Care for the Whole Family
A diagnosis of cancer has an impact on the entire family. Emotional support from family and friends can make a significant difference to the experience of survivorship, but knowing... -
Thriving with Cancer, with Dann Wonser
Dann Wonser, a 16-year lung cancer survivor and author of the book Second Wind – Thriving with Cancer, joins LUNGevity's Angela James to share learnings from his cancer journey and... -
The Healing Power of Stress, with Mike Verano
Mike Verano is a cancer survivor, author, and counselor with over 28 years of experience in the mental health field. Mike joins LUNGevity's Angela James to share concepts from his... -
Healing is an Art, with Genevieve De Renne
Genevieve De Renne is a caregiver and artist whose artwork has been featured on the cover of three recent issues of the Journal of Oncology Navigation & Survivorship. Genevieve... -
Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting
The development of new treatments for any disease relies on the collaborative efforts of many different stakeholders, such as scientists, clinicians, patient advocacy groups...
Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting
Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting
The development of new treatments for any disease relies on the collaborative efforts of many different stakeholders, such as scientists, clinicians, patient advocacy groups, regulators, and pharmaceutical and biotech companies.
During scientific conferences that happen throughout the year, stakeholders cobble together opportunities to discuss the current state of treatments and strategize ways to bring emerging lifesaving treatments to patients.
Each year, there is one key conference…
All About Biomarker Testing & KRAS+ Lung Cancer
All About Biomarker Testing & KRAS+ Lung Cancer
Patient Rosemary Conway was joined by LUNGevity's Dr. Amy Moore and Hatim Husain, an oncologist at UCSD, to discuss biomarker testing and progress in KRAS-positive lung cancer.
Improving Treatment for KRAS-Mutant Lung Cancer
Improving Treatment for KRAS-Mutant Lung Cancer
While targeted therapies have emerged in the past decade to improve treatment of non-small cell lung cancer (NSCLC) with some types of driver mutations (such as EGFR and ALK), lung adenocarcinomas with KRAS driver mutations have been notoriously difficult to study and treat.
KRAS is just one member of a large family of proteins, called RTKs (receptor tyrosine kinases), that span from the surface of the cell into the cell’s interior. This positioning allows RTKs to detect signals (such as…
Key Findings from ASCO 2022
Key Findings from ASCO 2022
Upal Basu Roy, PhD, MPH, LUNGevity's Executive Director of Research, speaks with Charles Rudin, MD, PhD, about the key findings from the recent meeting of the American Society for Clinical Oncology (ASCO) and what they mean for the lung cancer community.
We're Live-Tweeting from ASCO June 3-7!
We're Live-Tweeting from ASCO June 3-7!
LUNGevity’s Dr. Upal Basu Roy and Dr. Amy Moore will be live-tweeting from the American Society of Clinical Oncology (ASCO) annual meeting. Follow LUNGevity on Twitter and the hashtags #ASCO22 and #LCSM to be a part of the action. Times and topics of live-tweeted sessions are as follows:
Fri, Jun 3, 2022 | 2:00 PM – 5:00 PM EDT | Lung Cancer—Non-Small Cell Metastatic
Sun, Jun 5, 2022 | 9:00 AM – 10:15 AM EDT | Treatment Sequencing in Resectable Lung Cancer…
Lung Cancer Treatment Landscape: New Options and Ongoing Challenges
Lung Cancer Treatment Landscape: New Options and Ongoing Challenges
Drs. Upal Basu Roy, Amy Moore, and Dhru Deb discuss their recent publication in which they presented an analysis of the lung cancer drug pipeline. They talk about what it means for patients, new drugs under development for NSCLC and SCLC, and some of the ongoing challenges and opportunities this rapid growth means for the lung cancer community.
New Options in Adjuvant Therapy for Early-Stage NSCLC
New Options in Adjuvant Therapy for Early-Stage NSCLC
Historically, surgery has been the most effective treatment for patients with early-stage non-small cell lung cancer (NSCLC). While technological improvements, such as the development of minimally invasive techniques (such as video-assisted thoracoscopic surgery or VATS), have made surgeries safer for patients, the ability to cure early-stage NSCLC patients hasn’t improved significantly in recent decades. Even after successful surgeries that completely remove the visible tumor, about half of…
Highlights of the 2022 AACR meeting
Highlights of the 2022 AACR meeting
The American Association for Cancer Research (AACR) 2022 meeting was held in New Orleans from April 9 to 13. Doctors and researchers worldwide joined together virtually and in person to make this year’s meeting one of the largest gatherings since the start of the pandemic. They shared the many exciting developments in cancer research and treatment that emerged over the last year. This year’s meeting is another testament to “Science doesn’t stop, and scientists never sleep!” Here, we discuss…
KRAS: How It Started vs. How It’s Going
KRAS: How It Started vs. How It’s Going
On May 28, 2021, the United States Food & Drug Administration (FDA) approved sotorasib as the first targeted therapy for patients with KRAS G12C-positive non-small cell lung cancer (NSCLC). Both researchers and patients celebrated this historic breakthrough, which had been a goal since the KRAS oncogene was discovered 40 years ago. KRAS is a leading driver mutation in various forms of cancer. Still, targeting KRAS had failed for nearly four decades, leading many to believe that it was “…
All Things KRAS: A Conversation with Terri Conneran and Dr. Darryl McConnell
All Things KRAS: A Conversation with Terri Conneran and Dr. Darryl McConnell
On January 31, 2022, Amy Moore, PhD, brought us an update on KRAS. Dr. Moore, LUNGevity's Vice President of Global Engagement and Patient Partnerships, spoke with Terri Conneran, KRAS lung cancer survivor and founder of the KRAS Kickers; and Darryl McConnell, PhD, Research Site Head at Boehringer Ingelheim in Vienna, Austria.